Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-CoV-2 in End-Stage Renal Disease Patients on Chronic Hemodialysis: A Single-Center Study

Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-CoV-2 in End-Stage Renal Disease Patients on Chronic Hemodialysis: A Single-Center Study

<i>Background and Objectives</i>: In addition to a suboptimal and rapidly diminishing response to the coronavirus disease 2019 (COVID-19) vaccine, hemodialysis (HD) patients are at risk for developing a severe COVID-19 infection. In 2022, the combination of cilgavimab and tixagevimab (Ev...

Full description

Bibliographic Details
Main Authors: Mohammed Kamal Nassar, Alaa Sabry, Mohamed Elgamal, Zeinab Zeid, Dalia Abdellateif Abdelghany, Samar Tharwat
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:Medicina
Subjects:
tixagevimab
cilgavimab
Evusheld
hemodialysis
Online Access:https://www.mdpi.com/1648-9144/59/12/2109

Similar Items

Similar Items